NASDAQ:IMUX

Immunic (IMUX) Stock Forecast, Price & News

$1.47

+0.04 (+2.80%)

(As of 09/29/2023 ET)

Compare

Today's Range: $1.42
▼
$1.50
50-Day Range: $1.35
▼
$2.41
52-Week Range: $1.11
▼
$11.76

Volume: 231,154 shs
Average Volume: 222,104 shs
Market Capitalization: $65.56 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Immunic MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 240.1% Upside
$5.00 Price Target
Short Interest: Bearish
5.61% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.19) to ($1.89) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

586th out of 972 stocks

Pharmaceutical Preparations Industry

275th out of 445 stocks

3.3

Analyst's Opinion

Consensus Rating
Immunic has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.00, Immunic has a forecasted upside of 240.1% from its current price of $1.47.
Amount of Analyst Coverage
Immunic has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.61% of the outstanding shares of Immunic have been sold short.
Short Interest Ratio / Days to Cover
Immunic has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Immunic has recently increased by 4.60%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Immunic does not currently pay a dividend.
Dividend Growth
Immunic does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMUX.

3.3

News and Social Media Coverage

News Sentiment
Immunic has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Immunic this week, compared to 1 article on an average week.
Search Interest
5 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunic insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.50% of the stock of Immunic is held by insiders.
Percentage Held by Institutions
45.26% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Immunic are expected to grow in the coming year, from ($2.19) to ($1.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunic is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunic is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunic has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Immunic (NASDAQ:IMUX) Stock

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

IMUX Price History

30 days | 90 days | 365 days | Advanced Chart

IMUX Stock News Headlines

September 6, 2023 | finance.yahoo.com

Immunic to Participate in Industry and Investor Conferences in September

August 20, 2023 | proactiveinvestors.com

Immunic completes enrollment in trial of vidofludimus calcium in patients with progressive MS

October 1, 2023 | Legacy Research (Ad)

New Cash Law Will Be Disaster for Savers

New law has expert warning seniors and retirees to beware. There's a darker truth behind this financial bombshell...

August 18, 2023 | proactiveinvestors.com

Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment

August 4, 2023 | markets.businessinsider.com

Wedbush Sticks to Its Buy Rating for Immunic (IMUX)

August 3, 2023 | proactiveinvestors.com

Immunic CEO says Q2 results "couldn't be better"

August 3, 2023 | finance.yahoo.com

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 1, 2023 | finance.yahoo.com

Immunic to Participate in Investor and Scientific Conferences in August

October 1, 2023 | Legacy Research (Ad)

New Cash Law Will Be Disaster for Savers

New law has expert warning seniors and retirees to beware. There's a darker truth behind this financial bombshell...

July 28, 2023 | nasdaq.com

Wedbush Reiterates Immunic (IMUX) Outperform Recommendation

July 27, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Pro Medicus Limited (OtherPMCUF) and Immunic (IMUX)

July 27, 2023 | finance.yahoo.com

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update

July 24, 2023 | finance.yahoo.com

With 50% stake, Immunic, Inc. (NASDAQ:IMUX) seems to have captured institutional investors' interest

July 21, 2023 | proactiveinvestors.com

Immunic Inc eyeing "big step" for multiple sclerosis patients

June 29, 2023 | finance.yahoo.com

Immunic to Participate in Scientific and Investor Conferences in July

June 27, 2023 | fool.com

Immunic (NASDAQ: IMUX)

June 27, 2023 | finance.yahoo.com

Pleasing Signs As A Number Of Insiders Buy Immunic Stock

June 21, 2023 | proactiveinvestors.com

Immunic is developing a pipeline of oral therapies for chronic inflammatory and autoimmune diseases

May 30, 2023 | proactiveinvestors.com

Immunic ultimately hoping to "offer patients a new kind of treatment" for multiple sclerosis

May 30, 2023 | finance.yahoo.com

Immunic to Participate in Scientific and Investor Conferences in June

May 17, 2023 | proactiveinvestors.com

Immunic notes neuroprotective potential of vidofludimus calcium highlighted in preclinical data

May 17, 2023 | proactiveinvestors.com

Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program

May 16, 2023 | markets.businessinsider.com

Wedbush Keeps Their Buy Rating on Immunic (IMUX)

May 12, 2023 | msn.com

Recap: Immunic Q1 Earnings

May 12, 2023 | proactiveinvestors.com

Immunic Inc set to bring relief with encouraging results

May 11, 2023 | washingtonpost.com

Immunic: Q1 Earnings Snapshot

May 11, 2023 | finance.yahoo.com

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

See More Headlines

Receive IMUX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter.

IMUX Company Calendar

Last Earnings: 8/03/2023
Today: 9/30/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IMUX
CUSIP: N/A
CIK: 1280776
Web: www.immunic-therapeutics.com
Phone: (332) 255-9818
Fax: 858-673-6843
Employees: 75
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +240.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.44)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-120,410,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -132.61%
Return on Assets: -113.76%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.74
Quick Ratio: 4.74

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.56 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 44,600,000
Free Float: 42,588,000
Market Cap: $65.56 million
Optionable: Not Optionable
Beta: 2.03

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Duane D. Nash J.D. (Age 52)
M.B.A, M.B.A., M.D., Exec. Chairman
Comp: $433.4k

Dr. Daniel Vitt Ph.D. (Age 55)
CEO, Pres & Director
Comp: $728.4k

Mr. Glenn Whaley CPA (Age 55)
Chief Financial Officer
Comp: $522.21k

Dr. Andreas Muehler M.D. (Age 59)
Ph.D., Chief Medical Officer
Comp: $599.57k

Dr. Hella Kohlhof (Age 50)
Chief Scientific Officer

Jessica Breu
Head of Investor Relations & Communications

Mr. Inderpal Singh (Age 57)
Gen. Counsel

Mr. Patrick Walsh (Age 40)
Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMUX Stock - Frequently Asked Questions

Should I buy or sell Immunic stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMUX shares.
View IMUX analyst ratings or view top-rated stocks.
What is Immunic's stock price forecast for 2023?: 2 Wall Street analysts have issued 1-year price objectives for Immunic's stock. Their IMUX share price forecasts range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 240.1% from the stock's current price.
View analysts price targets for IMUX or view top-rated stocks among Wall Street analysts.
How have IMUX shares performed in 2023?: Immunic's stock was trading at $1.40 on January 1st, 2023. Since then, IMUX shares have increased by 5.0% and is now trading at $1.47.
View the best growth stocks for 2023 here.
When is Immunic's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IMUX earnings forecast.
How were Immunic's earnings last quarter?: Immunic, Inc. (NASDAQ:IMUX) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.02.

What other stocks do shareholders of Immunic own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and
What is Immunic's stock symbol?: Immunic trades on the NASDAQ under the ticker symbol "IMUX."
How do I buy shares of Immunic?: Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Immunic's stock price today?: One share of IMUX stock can currently be purchased for approximately $1.47.
How much money does Immunic make?: Immunic (NASDAQ:IMUX) has a market capitalization of $65.56 million. The company earns $-120,410,000.00 in net income (profit) each year or ($3.44) on an earnings per share basis.
How can I contact Immunic?: Immunic's mailing address is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. The official website for the company is www.immunic-therapeutics.com. The company can be reached via phone at (332) 255-9818, via email at jessica.breu@immunic.de, or via fax at 858-673-6843.

This page (NASDAQ:IMUX) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial